期刊文献+

多发性骨髓瘤治疗的现状与展望 被引量:3

Current status and future prospects for multiple myeloma
原文传递
导出
摘要 在过去几年中,多发性骨髓瘤的治疗取得了很大的进展。新型靶向治疗药物使骨髓瘤的治疗迈入了一个崭新的时代。各种不同作用机制药物的联合进一步改善了骨髓瘤的治疗效果。在新药治疗时代,对骨髓瘤细胞生物学特性的深刻把握,使得临床医生科学地制定抗瘤策略至关重要。对药物作用机制认识的不断深化也有助于最大限度地发挥药物治疗骨髓瘤的效果。文章就上述领域问题作一述评,以期引起广大同行的关注。 Many progresses for the treatment of multiple myeloma have been made since last decade. The application of novel target agents has brought the treatment of multiple myeloma into a new era. The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents. It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined. In this review, the author will review the current status and make a prospective discussion in this field.
作者 侯健
出处 《白血病.淋巴瘤》 CAS 2008年第5期321-322,共2页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 免疫抑制剂 蛋白酶抑制剂 Multiple myeloma Immunosuppressive agents Protease inhibitor
  • 相关文献

同被引文献39

  • 1曲东霞.沙利度胺联合小剂量MP方案化疗治疗老年多发性骨髓瘤的临床观察[J].大连医科大学学报,2007,29(3):249-251. 被引量:8
  • 2张方楹.多发性骨髓瘤治疗新进展[J].中外医疗,2008,27(27):12-17. 被引量:1
  • 3麦玉洁,李睿,邹德慧,王亚非,赵耀中,杨仁池,王建祥,肖志坚,韩明哲,钱林生,邱录贵.206例多发性骨髓瘤患者不同方案疗效分析[J].中华血液学杂志,2005,26(4):193-196. 被引量:37
  • 4Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006, 20: 1467-1473.
  • 5Terpos E, Roussou M, Dimopoulos MA. Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol, 2008, 4: 639-654.
  • 6Richardson PG, Hideshima T, Mitsiades C, et al. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw, 2007, 5: 149-162.
  • 7Wolf J. Richardson PG, Schuster M, et al. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol, 2008, 6: 755-760.
  • 8Singhal S, Mehta J, Desikan R, etal. Antltumor activity ofthalidomide in refractory multiple myoloma [ J ]. N Engl JMed, 1999, 341 ( 18 ) : 1565-1571.
  • 9Davies FE, Raje N,Hideshima T, eta l. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity inmultiplemyeloma[ J ]. Blood, 2001, 98( 1 ) : 210-216.
  • 10Johnson RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukemia [J]. Leuk Lymphoma,2002,43 (2): 351-354.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部